206 related articles for article (PubMed ID: 28212433)
1. Elevated GM3 plasma concentration in idiopathic Parkinson's disease: A lipidomic analysis.
Chan RB; Perotte AJ; Zhou B; Liong C; Shorr EJ; Marder KS; Kang UJ; Waters CH; Levy OA; Xu Y; Shim HB; Pe'er I; Di Paolo G; Alcalay RN
PLoS One; 2017; 12(2):e0172348. PubMed ID: 28212433
[TBL] [Abstract][Full Text] [Related]
2. High Performance Liquid Chromatography-Mass Spectrometry (LC-MS) Based Quantitative Lipidomics Study of Ganglioside-NANA-3 Plasma to Establish Its Association with Parkinson's Disease Patients.
Zhang J; Zhang X; Wang L; Yang C
Med Sci Monit; 2017 Nov; 23():5345-5353. PubMed ID: 29123078
[TBL] [Abstract][Full Text] [Related]
3. Lipidomics Prediction of Parkinson's Disease Severity: A Machine-Learning Analysis.
Avisar H; Guardia-Laguarta C; Area-Gomez E; Surface M; Chan AK; Alcalay RN; Lerner B
J Parkinsons Dis; 2021; 11(3):1141-1155. PubMed ID: 33814463
[TBL] [Abstract][Full Text] [Related]
4. Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease.
Ghauharali-van der Vlugt K; Langeveld M; Poppema A; Kuiper S; Hollak CE; Aerts JM; Groener JE
Clin Chim Acta; 2008 Mar; 389(1-2):109-13. PubMed ID: 18164265
[TBL] [Abstract][Full Text] [Related]
5. Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosides.
Di Pasquale E; Fantini J; Chahinian H; Maresca M; Taïeb N; Yahi N
J Mol Biol; 2010 Mar; 397(1):202-18. PubMed ID: 20114052
[TBL] [Abstract][Full Text] [Related]
6. Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson's Disease.
Alecu I; Bennett SAL
Front Neurosci; 2019; 13():328. PubMed ID: 31031582
[TBL] [Abstract][Full Text] [Related]
7. Lipid metabolic dysregulation is involved in Parkinson's disease dementia.
Dong MX; Wei YD; Hu L
Metab Brain Dis; 2021 Mar; 36(3):463-470. PubMed ID: 33433787
[TBL] [Abstract][Full Text] [Related]
8. Gangliosides profiling in serum of breast cancer patient: GM3 as a potential diagnostic biomarker.
Li Q; Sun M; Yu M; Fu Q; Jiang H; Yu G; Li G
Glycoconj J; 2019 Oct; 36(5):419-428. PubMed ID: 31297734
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
Blanz J; Saftig P
J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
[TBL] [Abstract][Full Text] [Related]
10. Metabolomics profiling reveals altered lipid metabolism and identifies a panel of lipid metabolites as biomarkers for Parkinson's disease related anxiety disorder.
Dong MX; Hu L; Wei YD; Chen GH
Neurosci Lett; 2021 Feb; 745():135626. PubMed ID: 33440238
[TBL] [Abstract][Full Text] [Related]
11. The Role of Lipids in Parkinson's Disease.
Xicoy H; Wieringa B; Martens GJM
Cells; 2019 Jan; 8(1):. PubMed ID: 30621069
[TBL] [Abstract][Full Text] [Related]
12. Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels.
Te Vruchte D; Sturchio A; Priestman DA; Tsitsi P; Hertz E; Andréasson M; Markaki I; Wallom KL; Platt F; Svenningsson P
Mov Disord; 2022 Oct; 37(10):2129-2134. PubMed ID: 35876461
[TBL] [Abstract][Full Text] [Related]
13. Elevation of gangliosides in four brain regions from Parkinson's disease patients with a GBA mutation.
Blumenreich S; Nehushtan T; Barav OB; Saville JT; Dingjan T; Hardy J; Fuller M; Futerman AH
NPJ Parkinsons Dis; 2022 Aug; 8(1):99. PubMed ID: 35933559
[TBL] [Abstract][Full Text] [Related]
14. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
[TBL] [Abstract][Full Text] [Related]
15. Serum lipid alterations in GBA-associated Parkinson's disease.
Guedes LC; Chan RB; Gomes MA; Conceição VA; Machado RB; Soares T; Xu Y; Gaspar P; Carriço JA; Alcalay RN; Ferreira JJ; Outeiro TF; Miltenberger-Miltenyi G
Parkinsonism Relat Disord; 2017 Nov; 44():58-65. PubMed ID: 28890071
[TBL] [Abstract][Full Text] [Related]
16. Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis.
Han W; Sapkota S; Camicioli R; Dixon RA; Li L
Mov Disord; 2017 Dec; 32(12):1720-1728. PubMed ID: 28880465
[TBL] [Abstract][Full Text] [Related]
17. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
18. Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease.
Wang X; Yu S; Li F; Feng T
Neurosci Lett; 2015 Jul; 599():115-9. PubMed ID: 25998655
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel biomarkers for Parkinson's disease by metabolomic technologies.
Hatano T; Saiki S; Okuzumi A; Mohney RP; Hattori N
J Neurol Neurosurg Psychiatry; 2016 Mar; 87(3):295-301. PubMed ID: 25795009
[TBL] [Abstract][Full Text] [Related]
20. Identification of Ganglioside GM3 Molecular Species in Human Serum Associated with Risk Factors of Metabolic Syndrome.
Veillon L; Go S; Matsuyama W; Suzuki A; Nagasaki M; Yatomi Y; Inokuchi J
PLoS One; 2015; 10(6):e0129645. PubMed ID: 26102277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
